Relic Technologies Reports Standalone Profitability Amidst Consolidated Losses

Relic Technologies Ltd reported a standalone net profit of Rs 0.21 crore for the quarter ended June 30, 2026, a significant increase from Rs 0.10 crore in the same period last year. However, the company's consolidated operations continued to incur losses, amounting to Rs 1.03 crore for the quarter.

Reader Takeaway: Standalone profit growth is positive, but consolidated losses and revenue drop need monitoring.

What just happened

Relic Technologies Ltd announced its unaudited financial results for the first quarter of the fiscal year ending June 30, 2026. The company achieved a standalone net profit of Rs 0.21 crore (Rs 21.47 lakh) on a total income of Rs 0.64 crore (Rs 64.15 lakh). This marks a substantial improvement from the Rs 0.10 crore (Rs 9.84 lakh) profit recorded in the corresponding quarter of the previous fiscal year.

Conversely, the consolidated financial statements revealed a net loss of Rs 1.03 crore (Rs 102.75 lakh) for the quarter. Consolidated income also saw a significant decline, falling to Rs 0.58 crore (Rs 57.86 lakh) from Rs 1.46 crore (Rs 145.72 lakh) in the prior year's comparable quarter.

Why this matters

The divergence between standalone profitability and consolidated losses highlights the performance of different business segments or entities within the group. For investors, the key takeaway is the positive standalone performance, which is offset by the overall group's financial performance. The commencement of new trading operations in pharmaceuticals and wellness sectors presents a potential growth avenue, but its impact on the consolidated results remains to be seen.

The backstory

Relic Technologies operates in a single business segment. The company recently ventured into trading activities involving pharmaceuticals, nutraceuticals, wellness products, healthcare products, chemicals, and allied products. This diversification aims to broaden the company's revenue streams.

What changes now

Investors will be closely watching how the newly launched trading operations in the pharma and wellness sectors contribute to the company's overall financial health, particularly its consolidated bottom line. The focus will be on the scalability and profitability of these new ventures.

Risks to watch

Despite the positive standalone results, the persistent consolidated losses and the significant drop in consolidated income are areas of concern. Investors need to monitor the effectiveness of the new trading business in turning around the group's performance and the potential for revenue volatility.

Peer comparison

(No specific peer comparison data was provided in the filing.)

Context metrics (time-bound)

• Standalone Income Growth: Q1 FY27 standalone income grew to Rs 0.64 crore from Rs 0.23 crore in Q1 FY26.
• Standalone Profit Growth: Q1 FY27 standalone net profit rose to Rs 0.21 crore from Rs 0.10 crore in Q1 FY26.
• Consolidated Loss: Q1 FY27 consolidated net loss was Rs 1.03 crore, an improvement from Rs 3.68 crore in Q1 FY26.

What to track next

Investors should track the progress and financial contribution of the new trading operations in the pharmaceutical and wellness sectors. Future quarterly results will indicate whether the company can leverage these new ventures to improve consolidated profitability.